Ken Griffin Aclaris Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	BUY	$1.15 - $4.59 $36,455 - $145,503	31,700 Added 3170.0%	32,700 $81,000
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.4 $2,576 - $3,220	-2,300 Reduced 69.7%	1,000 $1,000
Q2 2024 Aug 14, 2024	SELL	$1.01 - $1.36 $12,726 - $17,136	-12,600 Reduced 79.25%	3,300 $3,000
Q1 2024 May 15, 2024	SELL	$0.92 - $1.44 $16,192 - $25,344	-17,600 Reduced 52.54%	15,900 $19,000
Q4 2023 Feb 14, 2024	SELL	$0.64 - $6.49 $47,872 - $485,452	-74,800 Reduced 69.07%	33,500 $35,000
Q3 2023 Nov 14, 2023	BUY	$6.56 - $10.95 $143,664 - $239,804	21,900 Added 25.35%	108,300 $741,000
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $391,344 - $527,744	-49,600 Reduced 36.47%	86,400 $895,000
Q1 2023 May 15, 2023	BUY	$7.07 - $17.95 $939,603 - $2.39 Million	132,900 Added 4287.1%	136,000 $1.1 Million
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $44,423 - $56,947	3,100 New	3,100 $48,000

106

87.8M

293K

124K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $153M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.